TITAN PHARMACEUTICALS, INC. WARRANT TO PURCHASE SHARES OF STOCKWarrant Agreement • March 26th, 2018 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
THIS CERTIFIES THAT, for value received, _______________ and its assignees (“Warrant Holder”) are entitled to subscribe for and purchase _________ fully paid and nonassessable shares (the “Shares”) of common stock, $.001 par value (the “Common Stock of TITAN PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), at the price per share equal to $1.20 ( “Warrant Price”), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, (a) the term “Shares” shall mean the Common Stock and any stock into or for which such Common Stock may hereafter be converted or exchanged; (b) the term “Date of Grant” shall mean March 21, 2018, and (c) the term “Other Warrants” shall mean any warrant issued upon transfer or partial exercise of or in lieu of this Warrant. The term “Warrant” as used herein shall be deemed to include Other Warrants unless the context clearly requires otherwise. The Warrant Price and the number of Shares issuable upon exercise of thi
CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[*******]” OR OTHERWISE CLEARLY INDICATED. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES...Asset Purchase, Supply and Support Agreement • March 26th, 2018 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
THIS ASSET PURCHASE, SUPPLY AND SUPPORT AGREEMENT (the “Agreement”) is made as of March 21, 2018 (the “Effective Date”), by and between TITAN PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080-1921, United States (“Titan”), and L. MOLTENI & C. DEI F.LLI ALITTI SOCIETÀ DI ESERCIZIO S.P.A., a company organized and existing under the laws of Italy having its principal office at Strada Statale 67, Frazione Granatieri, Scandicci (Florence), Italy, (“Molteni”).
AMENDED AND RESTATED VENTURE LOAN AND SECURITY AGREEMENTVenture Loan and Security Agreement • March 26th, 2018 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
WHEREAS, Borrower, Horizon (as lender) and Horizon TFC (as collateral agent), are party to that certain Venture and Security Agreement, dated as of the Original Closing Date (as amended, restated, supplemented or otherwise modified from time to time prior to the effectiveness hereof, the “Original Agreement”);
RIGHTS AGREEMENTRights Agreement • March 26th, 2018 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This Rights Agreement (this “Agreement”) is dated March 21, 2018 by and between TITAN PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080-1921, United States (“Titan”), and L. MOLTENI & C. DEI FRATTELLI ALITTI SOCIETÀ DI ESERCIZIO S.P.A., a company organized and existing under the laws of Italy having its principal office at Strada Statale 67, Frazione Granatieri, Scandicci (Florence), Italy, or any of its affiliates, (“Molteni”).
